Publicacións en colaboración con investigadores/as de Universidade de Santiago de Compostela (40)

2024

  1. Enhanced Levels of Adiposity, Stretch and Fibrosis Markers in Patients with Coexistent Heart Failure and Atrial Fibrillation

    Journal of Cardiovascular Translational Research, Vol. 17, Núm. 1, pp. 13-23

  2. Enhancing patient outcomes: Integrating electronic cardiology consultation in primary care for cancer patients

    European Journal of Clinical Investigation

  3. Evaluating the decentralisation of the Spanish healthcare system: a data envelopment analysis approach

    BMJ Open, Vol. 14, Núm. 3

  4. Impact of a clinician-to-clinician electronic consultation in heart failure patients with previous hospital admissions

    European Heart Journal - Digital Health, Vol. 5, Núm. 1, pp. 9-20

  5. Pseudotransposition of the great leads

    PACE - Pacing and Clinical Electrophysiology, Vol. 47, Núm. 2, pp. 233-235

2023

  1. Circulating miR-451a Expression May Predict Recurrence in Atrial Fibrillation Patients after Catheter Pulmonary Vein Ablation

    Cells, Vol. 12, Núm. 4

  2. Clinical and cost-effectiveness results of an on-call program for pacemaker implantations

    Revista Espanola de Cardiologia, Vol. 76, Núm. 11, pp. 936-937

  3. Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study

    American Journal of Cardiovascular Drugs, Vol. 23, Núm. 5, pp. 583-593

  4. Effect of dapagliflozin on COVID-19 infection and risk of hospitalization

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 9, pp. 2335-2342

  5. Effects of guideline-directed medical therapy in patients with left bundle branch block-induced cardiomyopathy

    Revista Espanola de Cardiologia, Vol. 76, Núm. 4, pp. 238-244

  6. Endocardial ganglionated plexi ablation in a patient with cardioinhibitory carotid sinus syndrome

    Revista Espanola de Cardiologia, Vol. 76, Núm. 1, pp. 66-67

  7. Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis

    Journal of cardiovascular pharmacology, Vol. 81, Núm. 1, pp. 70-75

  8. Plasma miR-486-5p Expression Is Upregulated in Atrial Fibrillation Patients with Broader Low-Voltage Areas

    International Journal of Molecular Sciences, Vol. 24, Núm. 20

  9. Role of Soluble ST2 Biomarker in Predicting Recurrence of Atrial Fibrillation after Electrical Cardioversion or Pulmonary Vein Isolation

    International Journal of Molecular Sciences, Vol. 24, Núm. 18

2022

  1. Circulating miR-499a and miR-125b as Potential Predictors of Left Ventricular Ejection Fraction Improvement after Cardiac Resynchronization Therapy

    Cells, Vol. 11, Núm. 2

  2. Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 12

  3. Ethanol infusion in the vein of Marshall: A potential bail-out strategy in cardioneuromodulation procedures?

    HeartRhythm Case Reports, Vol. 8, Núm. 12, pp. 807-810

  4. Relaxin-2 plasma levels in atrial fibrillation are linked to inflammation and oxidative stress markers

    Scientific Reports, Vol. 12, Núm. 1

  5. Searching for genetic modulators of the phenotypic heterogeneity in Brugada syndrome

    PLoS ONE, Vol. 17, Núm. 3 March

  6. Semaglutide versus GLP-1 agonists. Effectiveness, safety, and quality of life in patients with diabetes mellitus 2. The SEVERAL study

    Farmacia Hospitalaria, Vol. 46, Núm. 6, pp. 372-379